LEXICON PHARMACEUTICALS, INC. Investing Cash Flow
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Investing Cash Flow of -$86.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$16.46M, a 206.32% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$70.26M, a 273.14% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $4.83M, a 91.01% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $52.13M, a 2.51% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $113.02M.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$15.38M.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$49.94M.
- LEXICON PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$71.08M, a 3468.63% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$86.72M 10-Q · filed 2026-08-06 | -$81.89M derived: sum of 3 quarters · filed 2026-08-06 | -$29.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$70.26M 10-Q · filed 2026-05-07 | -$65.43M derived: sum of 2 quarters · filed 2026-05-07 | -$13.31M derived: sum of 3 quarters · filed 2026-05-07 | $2.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $56.95M derived: sum of 2 quarters · filed 2026-03-05 | $72.44M derived: sum of 3 quarters · filed 2026-08-06 | $113.02M 10-K · filed 2026-03-05 |
| 2025-09-30 | $52.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $67.61M derived: sum of 2 quarters · filed 2026-08-06 | $108.19M 10-Q · filed 2025-11-06 | $161.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $56.06M 10-Q · filed 2026-08-06 | $109.77M derived: sum of 3 quarters · filed 2026-08-06 | $163.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $40.58M 10-Q · filed 2026-05-07 | $94.28M derived: sum of 2 quarters · filed 2026-05-07 | $147.75M derived: sum of 3 quarters · filed 2026-05-07 | $135.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $53.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $107.17M derived: sum of 2 quarters · filed 2026-03-05 | $94.85M derived: sum of 3 quarters · filed 2026-03-05 | -$15.38M 10-K · filed 2026-03-05 |
| 2024-09-30 | $53.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.15M derived: sum of 2 quarters · filed 2025-11-06 | -$69.08M 10-Q · filed 2025-11-06 | -$17.18M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$12.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$122.55M 10-Q · filed 2025-08-06 | -$70.65M derived: sum of 3 quarters · filed 2026-03-05 | -$109.97M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$110.22M 10-Q · filed 2025-05-14 | -$58.33M derived: sum of 2 quarters · filed 2026-03-05 | -$97.65M derived: sum of 3 quarters · filed 2026-03-05 | -$172.26M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $51.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.57M derived: sum of 2 quarters · filed 2026-03-05 | -$62.04M derived: sum of 3 quarters · filed 2026-03-05 | -$49.94M 10-K · filed 2026-03-05 |
| 2023-09-30 | -$39.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$113.93M derived: sum of 2 quarters · filed 2024-11-13 | -$101.84M 10-Q · filed 2024-11-13 | -$77.67M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | -$74.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$62.52M 10-Q · filed 2024-08-02 | -$38.34M derived: sum of 3 quarters · filed 2025-03-07 | -$115.54M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $12.09M 10-Q · filed 2024-05-02 | $36.27M derived: sum of 2 quarters · filed 2025-03-07 | -$40.93M derived: sum of 3 quarters · filed 2025-03-07 | -$54.58M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $24.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$53.02M derived: sum of 2 quarters · filed 2025-03-07 | -$66.67M derived: sum of 3 quarters · filed 2025-03-07 | -$71.08M 10-K · filed 2025-03-07 |
| 2022-09-30 | -$77.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$90.84M derived: sum of 2 quarters · filed 2023-11-08 | -$95.25M 10-Q · filed 2023-11-08 | -$89.16M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | -$13.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$18.06M 10-Q · filed 2023-08-04 | -$11.96M derived: sum of 3 quarters · filed 2024-03-25 | -$12.36M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | -$4.41M 10-Q · filed 2023-05-04 | $1.69M derived: sum of 2 quarters · filed 2024-03-25 | $1.29M derived: sum of 3 quarters · filed 2024-03-25 | $15.43M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $5.70M derived: sum of 2 quarters · filed 2024-03-25 | $19.83M derived: sum of 3 quarters · filed 2024-03-25 | $2.11M 10-K · filed 2024-03-25 |
| 2021-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $13.74M derived: sum of 2 quarters · filed 2022-11-09 | -$3.99M 10-Q · filed 2022-11-09 | $40.12M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $14.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$3.59M 10-Q · filed 2022-08-03 | $40.52M derived: sum of 3 quarters · filed 2023-03-03 | $256.32M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | -$17.72M 10-Q · filed 2022-05-05 | $26.38M derived: sum of 2 quarters · filed 2023-03-03 | $242.18M derived: sum of 3 quarters · filed 2023-03-03 | $320.25M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $44.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $259.90M derived: sum of 2 quarters · filed 2023-03-03 | $337.98M derived: sum of 3 quarters · filed 2023-03-03 | $380.76M 10-K · filed 2023-03-03 |
| 2020-09-30 | $215.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $293.88M derived: sum of 2 quarters · filed 2021-11-09 | $336.65M 10-Q · filed 2021-11-09 | $227.26M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $78.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $120.85M 10-Q · filed 2021-08-06 | $11.45M derived: sum of 3 quarters · filed 2022-03-10 | -$19.83M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $42.78M 10-Q · filed 2021-05-06 | -$66.62M derived: sum of 2 quarters · filed 2022-03-10 | -$97.90M derived: sum of 3 quarters · filed 2022-03-10 | -$105.35M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$109.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$140.68M derived: sum of 2 quarters · filed 2022-03-10 | -$148.13M derived: sum of 3 quarters · filed 2022-03-10 | -$155.85M 10-K · filed 2022-03-10 |
| 2019-09-30 | -$31.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$38.73M derived: sum of 2 quarters · filed 2020-10-30 | -$46.46M 10-Q · filed 2020-10-30 | $12.29M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$7.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$15.18M 10-Q · filed 2020-07-29 | $43.58M derived: sum of 3 quarters · filed 2021-03-12 | $99.97M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$7.73M 10-Q · filed 2020-04-27 | $51.02M derived: sum of 2 quarters · filed 2021-03-12 | $107.42M derived: sum of 3 quarters · filed 2021-03-12 | $154.79M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $58.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $115.15M derived: sum of 2 quarters · filed 2021-03-12 | $162.51M derived: sum of 3 quarters · filed 2021-03-12 | $169.58M 10-K · filed 2021-03-12 |
| 2018-09-30 | $56.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $103.76M derived: sum of 2 quarters · filed 2019-11-07 | $110.83M 10-Q · filed 2019-11-07 | -$24.94M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $47.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $54.43M 10-Q · filed 2019-08-01 | -$81.34M derived: sum of 3 quarters · filed 2020-03-12 | $5.71M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $7.06M 10-Q · filed 2019-05-01 | -$128.70M derived: sum of 2 quarters · filed 2020-03-12 | -$41.66M derived: sum of 3 quarters · filed 2020-03-12 | $15.13M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$135.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$48.72M derived: sum of 2 quarters · filed 2020-03-12 | $8.07M derived: sum of 3 quarters · filed 2020-03-12 | $50.52M 10-K · filed 2020-03-12 |
| 2017-09-30 | $87.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $143.83M derived: sum of 2 quarters · filed 2018-11-01 | $186.29M 10-Q · filed 2018-11-01 | $242.75M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $56.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $99.24M 10-Q · filed 2018-07-30 | $155.70M derived: sum of 3 quarters · filed 2019-03-15 | $189.60M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $42.45M 10-Q · filed 2018-05-03 | $98.91M derived: sum of 2 quarters · filed 2019-03-15 | $132.81M derived: sum of 3 quarters · filed 2019-03-15 | $194.35M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $56.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $90.36M derived: sum of 2 quarters · filed 2019-03-15 | $151.89M derived: sum of 3 quarters · filed 2019-03-15 | $18.25M 10-K · filed 2019-03-15 |
| 2016-09-30 | $33.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $95.43M derived: sum of 2 quarters · filed 2017-11-08 | -$38.21M 10-Q · filed 2017-11-08 | -$162.34M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $61.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$72.10M 10-Q · filed 2017-08-01 | -$196.24M derived: sum of 3 quarters · filed 2018-03-01 | -$118.47M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | -$133.64M 10-Q · filed 2017-05-04 | -$257.78M derived: sum of 2 quarters · filed 2018-03-01 | -$180.01M derived: sum of 3 quarters · filed 2018-03-01 | -$179.67M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | -$124.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$46.37M derived: sum of 2 quarters · filed 2018-03-01 | -$46.03M derived: sum of 3 quarters · filed 2018-03-01 | -$117.02M 10-K · filed 2018-03-01 |
| 2015-09-30 | $77.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $78.11M derived: sum of 2 quarters · filed 2016-11-07 | $7.12M 10-Q · filed 2016-11-07 | -$163.60M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$70.65M 10-Q · filed 2016-08-04 | -$241.37M derived: sum of 3 quarters · filed 2017-03-06 | -$220.86M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | -$70.99M 10-Q · filed 2016-05-05 | -$241.71M derived: sum of 2 quarters · filed 2017-03-06 | -$221.20M derived: sum of 3 quarters · filed 2017-03-06 | -$219.98M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | -$170.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$150.21M derived: sum of 2 quarters · filed 2017-03-06 | -$148.99M derived: sum of 3 quarters · filed 2017-03-06 | -$108.42M 10-K · filed 2017-03-06 |
| 2014-09-30 | $20.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $21.73M derived: sum of 2 quarters · filed 2015-11-09 | $62.30M 10-Q · filed 2015-11-09 | $102.07M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $41.79M 10-Q · filed 2015-08-07 | $81.56M derived: sum of 3 quarters · filed 2016-03-11 | $101.80M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $40.57M 10-Q · filed 2015-05-05 | $80.34M derived: sum of 2 quarters · filed 2016-03-11 | $100.58M derived: sum of 3 quarters · filed 2016-03-11 | $111.00M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $39.77M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $60.01M derived: sum of 2 quarters · filed 2016-03-11 | $70.44M derived: sum of 3 quarters · filed 2016-03-11 | $99.54M 10-K · filed 2016-03-11 |
| 2013-09-30 | $20.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $30.67M derived: sum of 2 quarters · filed 2014-11-06 | $59.77M 10-Q · filed 2014-11-06 | $53.04M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $39.53M 10-Q · filed 2014-08-07 | $32.80M derived: sum of 3 quarters · filed 2015-03-12 | $44.45M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $29.11M 10-Q · filed 2014-05-08 | $22.38M derived: sum of 2 quarters · filed 2015-03-12 | $34.02M derived: sum of 3 quarters · filed 2015-03-12 | $60.88M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | -$6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $4.91M derived: sum of 2 quarters · filed 2015-03-12 | $31.77M derived: sum of 3 quarters · filed 2015-03-12 | -$97.81M 10-K · filed 2015-03-12 |
| 2012-09-30 | $11.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $38.50M derived: sum of 2 quarters · filed 2013-11-12 | -$91.08M 10-Q · filed 2013-11-12 | -$73.05M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $26.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$102.72M 10-Q · filed 2013-08-01 | -$84.69M derived: sum of 3 quarters · filed 2014-03-07 | -$53.95M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | -$129.57M 10-Q · filed 2013-05-10 | -$111.54M derived: sum of 2 quarters · filed 2014-03-07 | -$80.80M derived: sum of 3 quarters · filed 2014-03-07 | -$54.30M derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | $18.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $48.77M derived: sum of 2 quarters · filed 2014-03-07 | $75.27M derived: sum of 3 quarters · filed 2014-03-07 | $69.95M 10-K · filed 2014-03-07 |
| 2011-09-30 | $30.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $57.24M derived: sum of 2 quarters · filed 2012-11-07 | $51.92M 10-Q · filed 2012-11-07 | -$93.18M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-06-30 | $26.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $21.18M 10-Q · filed 2012-08-02 | -$123.92M derived: sum of 3 quarters · filed 2013-03-11 | -$124.73M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-03-31 | -$5.32M 10-Q · filed 2012-05-03 | -$150.42M derived: sum of 2 quarters · filed 2013-03-11 | -$151.23M derived: sum of 3 quarters · filed 2013-03-11 | |
| 2010-12-31 | -$145.10M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | -$145.91M derived: sum of 2 quarters · filed 2013-03-11 | -$113.84M 10-K · filed 2013-03-11 | |
| 2010-09-30 | -$810.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $31.26M 10-Q · filed 2011-11-01 | ||
| 2010-06-30 | $32.07M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $11.88M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |